Bristol-Myers announces changes in R&D strategy

Bristol-Myers Squibb Co. (NYSE:BMY) said it will shift its R&D to a specialty biopharma model and will discontinue its discovery work in HCV, diabetes and neuroscience. A spokesperson said the move wi...